Skip to Content
Search Menu

Uveal melanoma: ESMO 2025 updates in 2 minutes

New data from ESMO 2025 highlight striking results for AnzuCell therapy and novel combination strategies in uveal melanoma. Associate Professor Marco Donia, MD, PhD, University of Copenhagen & Clinician-Scientist at Herlev Hospital, Denmark, presents the most promising studies and future perspectives for systemic treatment.
Marco Donia

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Related

Significant therapeutic advancement for patients with HER2-positive biliary tract cancer

/ Jan Andreasen
Breast cancerESMO25NBCN
Marco Donia

Metastatic melanoma: ESMO 2025 updates in 2 minutes

/ Marco Donia
ESMO25Melanoma Play the Video 2:34
Marco Donia

Neoadjuvant melanoma: ESMO 2025 updates in 2 minutes

/ Marco Donia
ESMO25Melanoma Play the Video 2:27
Teresa Macarulla

ESMO 2025: HER2-Targeted Therapy Advances in BTC

/ Teresa Macarulla
ESMO25NBCN Play the Video 4:06

Sustained efficacy and quality of life with darolutamide + ADT in mHSPC patients of all ages

/ Jan Andreasen
ESMO25Prostate cancer

RNA Expression Profiles May Guide Future Targeted Therapy in Urothelial Cancer

/ Jan Andreasen
Bladder cancerESMO25
Katharina Leuchte

ESMO 2025: High-Intensity Interval Training Promotes Immune Responses in mNSCLC Patients

/ Katharina Leuchte
ESMO25Lung cancer Play the Video 05:43

Combination Therapy with Enzalutamide and Radium-223 in mCRPC: Insights from the REASSURE Study

/ Igle Jan de Jong / Jan Andreasen
ESMO25

LBA20: Sacituzumab Govitecan Significantly Prolongs PFS versus Chemotherapy in Advanced Triple-Negative Breast Cancer

/ Jan Andreasen
Breast cancerESMO25NBCN
Back to top